002873.SHE Guiyang Xintian Pharmaceutical Co Ltd
- Market cap
- CNY 1.81B
- P/E
- 185.8x
- P/B
- 1.39x
- ROE
- 1.7%
- Dividend yield
- 2.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002873.SHE undervalued?
Graham numberThe Graham number of Guiyang Xintian Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guiyang Xintian Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guiyang Xintian Pharmaceutical Co Ltd yet.
Guiyang Xintian Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of gynecological, urinary tract, breast, thyroid, cardiovascular, anti-tumor, and d…
Full company profileGuiyang Xintian Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guiyang Xintian Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 633M | 682M | 694M | 773M | 751M | 970M | 1.09B | 954M | 858M | 750M | 671M |
| Gross Profit | 518M | 549M | 548M | 610M | 585M | 769M | 840M | 735M | 627M | 537M | 490M |
| Operating Income | 61.6M | 74.7M | 74.6M | 83.4M | 86.4M | 117M | 122M | 93.7M | 63.2M | 30.1M | 36.0M |
| EBITDA | 88.3M | 88.9M | 97.9M | 106M | 110M | 157M | 158M | 126M | 111M | 67.0M | 41.0M |
| Net Income | 57.1M | 66.1M | 71.0M | 71.4M | 74.1M | 101M | 112M | 80.9M | 52.3M | 9.11M | 22.3M |
| EPS | 0.33 | 0.32 | 0.31 | 0.32 | 0.31 | 0.41 | 0.46 | 0.33 | 0.24 | 0.04 | 0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 550M | 856M | 984M | 1.08B | 1.54B | 1.52B | 1.84B | 1.91B | 1.95B | 2.12B | 2.04B |
| Total Liabilities | 270M | 234M | 324M | 375M | 708M | 634M | 715M | 798M | 756M | 865M | 747M |
| Shareholders' Equity | 279M | 622M | 659M | 707M | 828M | 890M | 1.13B | 1.11B | 1.19B | 1.26B | 1.29B |
| Cash & Short-term Investments | 62.5M | 86.5M | 139M | 182M | 448M | 152M | 101M | 138M | 118M | 174M | 196M |
| Total Debt | 192M | 141M | 213M | 254M | 564M | 430M | 486M | 572M | 534M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 61.3M | 62.1M | 47.6M | 33.7M | 176M | 124M | 75.8M | 77.8M | 88.1M | 83.7M | - |
| Capital Expenditure | 13.8M | 105M | 40.5M | 156M | 68.1M | 106M | 129M | 102M | 61.5M | 51.6M | 58.7M |
| Free Cash Flow | 47.6M | -43.2M | 7.05M | -122M | 108M | 18.6M | -53.4M | -23.9M | 26.7M | 32.1M | 176M |
| Ratios | |||||||||||
| ROE | 20.4% | 10.6% | 10.8% | 10.1% | 8.9% | 11.3% | 9.9% | 7.3% | 4.4% | 0.7% | 1.7% |
| ROA | 10.4% | 7.7% | 7.2% | 6.6% | 4.8% | 6.6% | 6.0% | 4.2% | 2.7% | 0.4% | 1.1% |
| Net Profit Margin | 9.0% | 9.7% | 10.2% | 9.2% | 9.9% | 10.4% | 10.3% | 8.5% | 6.1% | 1.2% | 3.3% |
| Debt to Equity | 0.69x | 0.23x | 0.32x | 0.36x | 0.68x | 0.48x | 0.43x | 0.51x | 0.45x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guiyang Xintian Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.28%
- Forward dividend
- 0.03 CNY
- Payout ratio
- 454.6%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 41.4M | 0.17 | 454.6% |
| 2024 | CNY 35.1M | 0.16 | 67.0% |
| 2023 | CNY 42.5M | 0.17 | 52.6% |
| 2022 | CNY 19.9M | 0.08 | 17.8% |
| 2021 | CNY 14.0M | 0.06 | 13.9% |
| 2020 | CNY 11.5M | 0.05 | 15.5% |
| 2019 | CNY 5.78M | 0.03 | 8.1% |
| 2018 | CNY 21.9M | 0.10 | 30.8% |
| 2017 | CNY 19.7M | 0.10 | 29.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Oct 28, 2022.
Who owns Guiyang Xintian Pharmaceutical Co Ltd
- Insiders 33.17%
- Institutions 3.83%
- Public & others 63.01%
- Shares outstanding 244M
- Free float 162M
Guiyang Xintian Pharmaceutical Co Ltd company profile
- Company name
- Guiyang Xintian Pharmaceutical Co Ltd
- Ticker
- 002873.SHE
- ISIN
- CNE100002QB5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,388
- Fiscal year end
- December
- Address
- No. 3 Gaoxin North Road, Guiyang, China, 550000
- Phone
- 86 851 8631 7787
- Website
- gyxtyy.com
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of gynecological, urinary tract, breast, thyroid, cardiovascular, anti-tumor, and dental diseases, as well as for oral health; and cold, heat-clearing, and blood-tonifying remedies. The company also engages in research and development; consulting; scientific research; accommodation and catering; technology promotion; pharmaceutical research and development; and health food processing activities. Guiyang Xintian Pharmaceutical Co.,Ltd. was founded in 1995 and is based in Guiyang, China.
Guiyang Xintian Pharmaceutical Co Ltd management
5- Mr. Da Lun DongGM & Chairman of the Board · born 1964
- Mr. Jin Hua WangVice Chairman & Deputy GM · born 1967
- Ms. Zhihui ZengCFO & Accounting Supervisor · born 1973
- Mr. Guangping WangDeputy GM, Director & Board Secretary · born 1970
- Mr. Mao Chen WeiDeputy General Manager · born 1983